Published on 22/12/2025
Case Study: Navigating the Orphan Drug Pathway for Successful Approval
Background: Understanding the Orphan Drug Pathway
The Orphan Drug Act (1983) in the U.S. and corresponding regulations in the EU were created to incentivize the development of therapies for rare diseases—conditions affecting fewer than 200,000 individuals in the U.S. or fewer than 5 in 10,000 in the EU. Regulatory incentives such as market exclusivity, tax credits, fee waivers, and grants make the orphan drug pathway an essential regulatory strategy for biotech firms targeting rare and ultra-rare conditions.
This case study explores the journey of Strensiq (asfotase alfa), a recombinant enzyme replacement therapy developed for hypophosphatasia (HPP), a rare, inherited metabolic disorder. Its approval story illustrates how orphan designation can support successful drug development despite small population challenges.
Disease Overview: Hypophosphatasia (HPP)
HPP is an ultra-rare disorder characterized by defective bone mineralization due to mutations in the ALPL gene. Clinical presentations vary widely, from perinatal lethal forms to milder adult-onset forms. Before Strensiq, no approved treatments existed for severe pediatric-onset HPP, making it a textbook case of high unmet medical need.
Patients suffer from respiratory failure, seizures, skeletal deformities, and high mortality in infancy. The rarity of
Development Milestones and Orphan Designation
Alexion Pharmaceuticals pursued an orphan designation early in development:
- FDA Orphan Designation: Received in 2008
- EMA Orphan Designation: Granted in 2008
- Breakthrough Therapy Designation: Awarded by FDA in 2013
The company leveraged compassionate use programs and patient registries to collect longitudinal natural history and biomarker data. Early trials focused on improving serum alkaline phosphatase levels, growth velocity, and radiographic skeletal improvements, which served as surrogate endpoints.
Trial Design: Using Adaptive and Ethical Approaches
Given the ultra-rare nature and ethical considerations, randomized controlled trials were not feasible. Instead, the sponsor adopted a single-arm, open-label design with historical controls. Primary endpoints included:
- Radiographic Global Impression of Change (RGI-C)
- Growth velocity over 48 weeks
- Improved respiratory function
While the sample size was small (n = 11–20 across studies), the consistency of clinical improvement and survival was sufficient to demonstrate clinical benefit under the FDA Accelerated Approval framework.
Approval Timeline and Regulatory Interactions
The timeline of development demonstrates how expedited pathways reduce delays:
| Milestone | Timeline |
|---|---|
| Pre-IND Meeting with FDA | 2007 |
| Orphan Designation (FDA + EMA) | 2008 |
| Breakthrough Therapy Designation | 2013 |
| NDA Submission | 2014 |
| FDA Approval | October 2015 |
| EMA Approval | August 2015 (under exceptional circumstances) |
Both agencies emphasized the need for post-marketing data collection and long-term outcome validation. Strensiq also qualified for 7-year market exclusivity in the U.S. and 10 years in the EU.
Additional case study resources available at the Japan RCT Portal.
Key Regulatory Levers That Facilitated Approval
This approval case succeeded due to a blend of:
- Early orphan designation: Unlocking incentives like protocol assistance, tax credits, and reduced fees
- Adaptive trial design: Using real-world data and historical controls to supplement limited sample size
- Close regulatory dialogue: Through Breakthrough and Scientific Advice programs
- Flexible endpoints: Leveraging surrogate markers tied to biological plausibility and natural history
The regulator’s willingness to accept alternative endpoints played a vital role. Without randomized comparative data, the strength of biologic plausibility and patient-reported outcomes (PROs) became essential pillars.
Post-Marketing Commitments and Real-World Evidence (RWE)
Following approval, Alexion committed to:
- Maintaining a global patient registry for long-term follow-up
- Conducting Phase IV studies in adult-onset HPP
- Reporting safety data through periodic safety update reports (PSURs)
The RWE generated from these initiatives further validated the clinical utility of Strensiq in broader patient populations.
Impact on the Rare Disease Ecosystem
This case became a precedent for future rare disease drug developers. It demonstrated that:
- Well-designed, small trials can lead to approval when supported by strong natural history and mechanistic rationale
- Regulatory flexibility is achievable with transparent, high-quality engagement
- Orphan pathway incentives can offset the high development costs associated with rare conditions
It also empowered patient advocacy groups to become more active in trial design and data collection.
Lessons for Sponsors Pursuing the Orphan Pathway
Key takeaways from the Strensiq approval include:
- Start early: File for orphan designation during preclinical development
- Engage with agencies: Use pre-IND, scientific advice, and protocol assistance meetings
- Leverage registries: Build natural history data alongside development
- Plan for lifecycle: Include follow-up indications and global expansion
Integrating regulatory, clinical, and patient engagement strategies from the outset can de-risk rare disease programs substantially.
Conclusion: A Blueprint for Rare Disease Drug Development
The Strensiq case exemplifies how leveraging the orphan drug pathway, creative trial design, and early regulatory engagement can lead to successful market entry—even for ultra-rare conditions. This model holds powerful lessons for biotechs and pharma companies aiming to serve neglected patient populations. With the right strategy, data, and communication, regulatory success in rare diseases is attainable and impactful.